Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-08

Clinical Trial Update: Pembrolizumab and EDP1503 in Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab in combination with EDP1503 for advanced melanoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EDP1503 (EDP1503)
  • KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Chicago | Conditions: Melanoma (Skin), Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2025-12-08